Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TDIC

Dreamland Ltd

3.61

Jul 14 • 04:00AM ET -0.27 (-6.96%)

Communication Services Advertising Agencies Hong Kong Nano NASD

Peers: BAOS CHR CNET DRCT KRKR VSME YDKG HAO SOPA STFS

Index	-
Market Cap	5.45M
Enterprise Value	3.12M
Income	-4.26M
Sales	7.02M
Book/sh	0.54
Cash/sh	2.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jul 23, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	0.78
P/B	6.65
P/C	1.54
P/FCF	-
EV/EBITDA	-
EV/Sales	0.44
Quick Ratio	1.67
Current Ratio	1.68
Debt/Eq	0.30
LT Debt/Eq	0.18
Option/Short	No / Yes

EPS (ttm)	-0.56
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	256.99% -
EPS Y/Y TTM	-422.78%
Sales Y/Y TTM	14.95%
EPS Q/Q	-1242.32%
Sales Q/Q	28.78%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	98.37%
Insider Trans	78.15%
Inst Own	0.01%
Inst Trans	-
ROA	-55.47%
ROE	-181.62%
ROIC	-89.77%
Gross Margin	9.69%
Oper. Margin	-71.35%
Profit Margin	-60.65%
SMA20	-32.49%
SMA50	-84.91%
SMA200	-95.02%
Trades

Shs Outstand	7.20M
Shs Float	0.62M
Short Float	1.49%
Short Ratio	0.01
Short Interest	0.01M
52W High	987.50 -99.63%
52W Low	3.00 20.33%
Volatility	17.37% 23.20%
ATR (14)	6.36
RSI (14)	45.74
Beta	6.05
Rel Volume	0.01
Avg Volume	1.63M
Volume	1,073

Perf Week	-11.30%
Perf Month	-53.91%
Perf Quarter	-74.91%
Perf Half Y	-85.49%
Perf YTD	-84.44%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	3.88
Price	3.61
Change	-6.96%

Jul-01-26 01:02PM	Compromised Advisor Credentials Used in Pump-and-Dump Schemes (Wealth Management) -5.48%
May-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +30.00%
May-13-26 10:30AM	BC-Most Active Stocks (Associated Press) +876.69%
May-12-26 11:13AM	AI Image Platform Partnership Expands Dreamlands Push Beyond Event Management (TDIC) (InvestorsHub) +126.92%
10:30AM	BC-Most Active Stocks (Associated Press)
05:12AM	Loading…
05:12AM	Dreamland Limited's Subsidiary Trendic International Limited and LinkFung Innovation Limited Enter Into MoU to Explore Development, Implementation, and Deployment of a Comprehensive AI-Powered Intelligent Image Library Platform (GlobeNewswire)
Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +45.11%
Dec-05-25 07:55AM	Dreamland Limited Secures $18 Million Equity Purchase Agreement (GlobeNewswire) +40.21%
Nov-28-25 06:16AM	Dreamland Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +9.82%
Jul-24-25 03:17PM	Dreamland Limited Announces Closing of Initial Public Offering (GlobeNewswire)
Jul-22-25 02:38PM	Dreamland Limited Announces Pricing of Initial Public Offering (GlobeNewswire)

Dreamland Ltd. is an event management service provider specializing in the organization, planning, promotion, and management of themed experience events. It handles a wide variety of public and private events, including trade shows, conferences, concerts, exhibitions, charity galas, brand promotions, and internal corporate events. The company was founded by Seto Wai Yue in 2016 and is headquartered in Hong Kong.

FounderMs. Wai Yue Seto

Chief Financial OfficerMr. Wai Kit Lee

Head of Design & Merchandising Department and DirectorMs. Sze Man Tse

General ManagerMr. Kai Chung Luk

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seto Wai Yue	Chief Executive Officer	Jul 07 '26	Buy	3.75	652,000	2,445,000	749,890	Jul 13 06:05 AM

Peers: CRML EMAT MP ALM USAR TMC UAMY BHP RIO FCX

| Held by: REMX APIE WEPN MSSM CCSO WDIG

Index	-
Market Cap	893.30M
Enterprise Value	831.93M
Income	-53.95M
Sales	0.00M
Book/sh	3.22
Cash/sh	1.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jun 21, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.67
P/C	13.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.00
Current Ratio	4.03
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.63
EPS next Y	-0.24
EPS next Q	-0.35
EPS this Y	-646.65%
EPS next Y	72.87%
EPS next 5Y	-
EPS past 3/5Y	9.31% -49.42%
Sales past 3/5Y	- -
EPS Y/Y TTM	-48.46%
Sales Y/Y TTM	-
EPS Q/Q	-73.26%
Sales Q/Q	-
Earnings	Mar 12 BMO
EPS/Sales Surpr.	-150.00% -100.00%

Insider Own	-
Insider Trans	-
Inst Own	13.07%
Inst Trans	-12.22%
ROA	-44.04%
ROE	-50.48%
ROIC	-48.36%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.54%
SMA50	-27.79%
SMA200	-36.63%
Trades

Shs Outstand	36.21M
Shs Float	33.93M
Short Float	2.25%
Short Ratio	2.64
Short Interest	0.76M
52W High	61.45 -59.85%
52W Low	21.66 13.90%
Volatility	6.34% 6.91%
ATR (14)	2.14
RSI (14)	33.94
Beta	1.64
Rel Volume	0.00
Avg Volume	289.34K
Volume	0

Perf Week	-13.01%
Perf Month	-27.84%
Perf Quarter	-22.64%
Perf Half Y	-43.01%
Perf YTD	-31.82%
Perf Year	-25.02%
Perf 3Y	225.46%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	58.95
Prev Close	24.67
Price	24.67
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	BTIG Research	Buy	$40
Jan-13-26	Initiated	William Blair	Outperform
Aug-20-25	Initiated	Roth Capital	Buy	$64
Oct-10-24	Initiated	B. Riley Securities	Buy	$30

Jul-07-26 07:51PM	IperionX Announces Pricing of Public Offering of American Depositary Shares (GlobeNewswire) -8.85% -7.70%
Jul-02-26 08:30AM	IperionX Completes Strategic Camden Acquisition - Unlocking Ultra-High-Grade Critical Minerals to Accelerate U.S. Supply Chain (GlobeNewswire)
Jul-01-26 08:30AM	IperionX Awarded Up to US$6.6M by OSW-SWIB to Scale U.S. Titanium Plate for Defense Applications (GlobeNewswire)
Jun-15-26 08:30AM	IperionX to Acquire Rights to Rare Earth and Critical Mineral Assets Adjacent to Titan Project (GlobeNewswire)
Jun-10-26 08:30AM	IperionX: Titan Definitive Feasibility Study (DFS) Presentation (GlobeNewswire) -5.13%
08:00AM	Loading…
Jun-04-26 08:00AM	IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project (GlobeNewswire)
Jun-01-26 08:30AM	U.S. Army Testing Shows Iperionx Titanium Fasteners Exceed Grade 8 Steel Torque-To-Yield Performance (GlobeNewswire) +7.76%
May-21-26 08:30AM	IperionX Commissions Six-Axis Powder Metallurgy Press, Expanding U.S. Titanium Component Manufacturing Capabilities (GlobeNewswire)
May-04-26 11:45AM	Tungsten Reshoring Goes Public: Western Star Files DIBC Application as APT Prices Surge ~900% YoY and the U.S. Defense Procurement Cliff Closes In (PR Newswire)
Apr-27-26 09:00AM	Iperionx Webinar - Investor Update (GlobeNewswire) +10.94%
08:30AM	IperionX - March 2026 Quarterly Report (GlobeNewswire)
Mar-30-26 09:51AM	Iperionx - Change of Directors and Officers Ownership (GlobeNewswire)
Mar-18-26 08:00AM	Small Ohio Company's Chemistry Breakthrough Could Have Major Defense Implications (PR Newswire) -6.58%
Mar-16-26 11:30AM	IperionX Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile) -15.57%
Mar-13-26 10:50AM	America Is Closing the Gap in the Rare Earth Supply Chain Race - OilPrice.com Market Commentary (PR Newswire) -14.03%
12:01AM	Loading…
Mar-05-26 12:01AM	IPX- A Titanium Play for this Supply Shortfall Era (MoneyShow)
Mar-04-26 09:40AM	Has First Majestic Silver (AG) Outpaced Other Basic Materials Stocks This Year? (Zacks)
Feb-27-26 05:00AM	Magnet Wars: How the U.S. Plans to Break Chinas Grip on Rare Earths (Oilprice.com)
Feb-02-26 09:55AM	Does IperionX Limited Sponsored ADR (IPX) Have the Potential to Rally 28.18% as Wall Street Analysts Expect? (Zacks)
08:30AM	IperionX - 2026 Letter to Shareholders (GlobeNewswire)
Jan-30-26 08:30AM	IperionX - December 2025 Quarterly Report (GlobeNewswire) -5.45%
Jan-27-26 07:57AM	3 Rare Earth Stocks to Watch as USAR Rallies on Washington Support (Zacks)
Jan-25-26 06:50PM	IperionX (IPX) Climbs 28.4% on New Govt Deal (Insider Monkey)
Jan-23-26 09:40AM	Is IperionX Limited Sponsored ADR (IPX) Outperforming Other Basic Materials Stocks This Year? (Zacks) +8.01%
Jan-22-26 08:30AM	IperionX Receives Prototype Purchase Order for U.S. Army Heavy Ground Combat Systems (GlobeNewswire) +7.31%
Jan-16-26 08:30AM	IperionX Receives Final $4.6M In DoW Funding and 290 Metric Tons of Titanium Scrap from U.S. Government (GlobeNewswire)
Dec-15-25 08:30AM	IperionX and Carver Pump to Accelerate Critical Component Production for U.S. Navy Ships (GlobeNewswire) -5.02%
Nov-17-25 08:30AM	IperionX Response to Short Seller Report (GlobeNewswire)
Oct-30-25 08:30AM	IperionX - September 2025 Quarterly Report (GlobeNewswire)
Sep-27-25 08:40AM	IperionX receives $25M in U.S. funding to accelerate titanium production (TipRanks)
08:30AM	Loading…
Sep-26-25 08:30AM	IperionX Receives a Further $25M in U.S. Government Funding to Accelerate Titanium Production Scale-Up (GlobeNewswire) +5.36%
Sep-09-25 01:02AM	Iperionx Ltd (IPX) Ramping up Titanium Buildout Amid Soaring Demand (Insider Monkey) -9.86%
Sep-02-25 08:30AM	IperionX Accelerates U.S. Titanium Buildout to Deliver Largest Scale and Lowest Unit-Cost Production (GlobeNewswire)
Aug-26-25 08:30AM	IperionX Receives $12.5M U.S. Government Funding to Accelerate Expansion of U.S. Titanium Production (GlobeNewswire)
Aug-07-25 08:30AM	IperionX Granted Up to US$150 Million in Tax-Exempt Private Activity Bond Issuance Capacity (GlobeNewswire)
Jul-25-25 09:40AM	Is Crown Holdings (CCK) Stock Outpacing Its Industrial Products Peers This Year? (Zacks)
Jul-23-25 08:30AM	IperionX - June 2025 Quarterly Report (GlobeNewswire) +6.96%
Jul-14-25 12:54PM	Fastenal Q2 Earnings & Sales Beat Estimates, Stock Rises (Zacks)
Jun-11-25 08:30AM	IperionX Secures First U.S. Army Task Order Under US$99 Million SBIR Phase III Contract (GlobeNewswire)
Jun-10-25 07:30AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-05-25 08:30AM	IperionX Awarded U.S. Department of Defense SBIR Phase III Contract for Up to US$99M (GlobeNewswire) +19.74%
May-05-25 12:50PM	Fidelity International Discovery Fund Q1 2025 Commentary (Seeking Alpha)
Apr-15-25 08:30AM	IperionX March 2025 Quarterly Report (Business Wire) +14.66%
Apr-08-25 08:30AM	IperionX Commences Titan Critical Minerals Project Definitive Feasibility Study With U.S. Government Support (Business Wire) -5.87%
Apr-01-25 08:30AM	IperionX Receives U.S. EXIM Bank Board Approval for a $11M Loan to Produce All-American Titanium Products (Business Wire)
Mar-13-25 08:30AM	IperionX Interim Financial Report for the Six Months Ended December 31, 2024 (Business Wire)
Mar-11-25 08:30AM	IperionX Enhances Board With Appointment of Senior U.S. Directors (Business Wire)
Feb-18-25 08:30AM	IperionX Awarded $47.1M by the U.S. DoD to Secure U.S. Titanium Supply Chains (Business Wire) +15.12%
Feb-06-25 08:30AM	IperionX Letter to Shareholders (Business Wire)
Jan-28-25 08:30AM	IperionX December 2024 Quarterly Report (Business Wire)
Nov-26-24 08:30AM	IperionX Completes Acquisition of Breakthrough Titanium Technologies (Business Wire)
Aug-14-24 08:30AM	IperionX Achieves Major Milestone With First Successful Titanium Furnace Production Run (Business Wire) +6.84%
Jul-02-24 12:00PM	IperionX and Aperam Partnership to Advance a Circular Titanium Supply Chain (Business Wire) +7.51%
May-01-24 08:30AM	IperionX and Vegas Fastener to Co-Produce Titanium Fasteners for U.S. Army (Business Wire)
Apr-26-24 08:30AM	IperionX Titanium HAMR Furnace Installation Complete (Business Wire)
Apr-15-24 08:30AM	IperionX Partners With United Stars for U.S. Sourced Titanium Manufacturing (Business Wire) -5.10%
Feb-14-24 08:30AM	IperionX Drives Towards Commercial Scale Titanium Metal Production (Business Wire) +10.47%
Jan-16-24 08:30AM	IperionX Letter to Shareholders (Business Wire)
Nov-29-23 09:00AM	IperionX 2023 Sustainability Report (Business Wire)
Nov-08-23 08:30AM	IperionX Completes US$16.7M Placement to Re-shore U.S. Titanium Production (Business Wire)
Nov-01-23 08:30AM	IperionX Receives US$12.7M U.S. Department of Defense Grant for Domestic Titanium Production (Business Wire) +18.69%
Oct-19-23 08:30AM	IperionX Receives US$11.5 Million LOI From EXIM Bank for U.S. Titanium Production (Business Wire) -13.77%
Oct-09-23 08:30AM	IperionX Company Presentation (Business Wire)
Oct-02-23 08:30AM	GKN Aerospace Partners With IperionX to Advance Sustainable Titanium Manufacturing (Business Wire)
Sep-07-23 08:30AM	IperionX to Produce Titanium Plate for U.S. Army Testing (Business Wire) +10.80%
Sep-06-23 08:30AM	IperionX and Heroux-Devtek Partner for Aerospace Titanium Recycling (Business Wire)
Aug-28-23 08:30AM	Titan Project Development Update (Business Wire)
Aug-23-23 08:30AM	IperionX Earns International Recognition With R&D 100 Award (Business Wire)
Aug-17-23 08:30AM	IperionX to Produce Titanium Plate for Testing by Lockheed Martin (Business Wire)
Aug-15-23 08:30AM	IperionX Receives Key Permits for Development of the Titanium & Rare Earth Mineral Rich Titan Project (Business Wire)
Jul-31-23 08:30AM	IperionX Receives Key Permits for Titanium Metal Production in Virginia (Business Wire)
Jul-10-23 08:30AM	IperionX and Aperam Recycling Partner to Create 100% Recycled Titanium Supply Chain (Business Wire)
Jun-15-23 08:00AM	IperionX Achieves First UL Validated 100% Recycled Titanium (Business Wire) -7.10%
Jun-13-23 08:00AM	IperionX to Produce Titanium Components for Ford Motor Company (Business Wire) +99.10%
Apr-27-23 08:30AM	IperionX Plans to Build the Worlds Largest 100% Recycled Titanium Metal Powder Facility By 2025 (Business Wire)
Apr-26-23 08:30AM	IperionX Releases Life Cycle Assessment of 100% Recycled Titanium Powder (Business Wire)
Apr-20-23 08:30AM	IperionX Green Hydrogen Market Assessment (Business Wire)
Mar-28-23 08:00AM	IperionX & Canyon Bicycles Partner to Implement Sustainability Improvements in the Bicycle Industry Supply Chain (Business Wire)

IperionX Ltd. engages in the development of low carbon titanium for advanced industries, including space, aerospace, electric vehicles and 3D printing. It produces titanium metal powders from titanium scrap at its operational pilot facility in Utah and intends to scale production at a Titanium Demonstration Facility in Virginia. The company was founded by Anastasios Arima and Scott Sparks on May 5, 2017 and is headquartered in Charlotte, NC.

B.E.Mr. Todd William Hannigan B. Eng (Hons)

FounderMr. Anastasios Arima B.Com.

President & Chief Strategy OfficerMr. Toby Edgcumbe Symonds

Co-founder & Chief Operating OfficerMr. W. Scott Sparks

Chief Financial OfficerMs. Marcela Rocha Barbosa De Castro

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arima Anastasios	Chief Executive Officer	Jul 10 '26	Buy	3.58	138,720	497,228	12,455,502	Jul 13 08:38 AM
Hannigan Todd	Executive Chairman	Jul 13 '26	Buy	3.59	300,000	1,075,980	26,633,334	Jul 13 08:16 AM
Hannigan Todd	Executive Chairman	Jul 10 '26	Buy	3.58	225,000	805,185	26,333,334	Jul 13 08:16 AM
Arima Anastasios	Chief Executive Officer	Apr 28 '26	Buy	4.49	110,000	493,625	12,316,782	Apr 30 07:38 AM
Hannigan Todd	Executive Chairman	Apr 29 '26	Buy	4.20	260,000	1,091,766	26,108,334	Apr 29 09:51 PM
Hannigan Todd	Executive Chairman	Apr 28 '26	Buy	4.48	220,000	986,018	25,848,334	Apr 29 09:51 PM
Symonds Toby Edgcumbe	President	Mar 27 '26	Buy	23.87	11,000	262,552	11,000	Mar 30 09:23 AM
Tripeny R Tony	Director	Mar 27 '26	Buy	23.76	4,187	99,464	4,187	Mar 30 09:08 AM
Hannigan Todd	Director	Mar 27 '26	Buy	3.20	225,225	720,923	25,628,334	Mar 30 08:57 AM
Arima Anastasios	Chief Executive Officer	Mar 27 '26	Buy	3.74	479,800	1,793,110	12,206,782	Mar 30 08:38 AM

CMC Commercial Metals Co daily Stock Chart

Peers: ATI CLF GGB NUE STLD RS TX MT SID AA

| Held by: VTI IJH VB IWM XME VBR VXF IWN PAVE MDY

Index	RUT
Market Cap	7.04B
Enterprise Value	10.11B
Income	595.11M
Sales	8.85B
Book/sh	40.94
Cash/sh	5.09
Dividend Est.	0.76 (1.19%)
Dividend TTM	0.76 (1.19%)
Dividend Ex-Date	Jul 06, 2026
Dividend Gr. 3/5Y	8.74% 8.45%
Payout	97.02%
Employees	12690
IPO	Jul 06, 1962

P/E	12.00
Forward P/E	9.02
PEG	0.31
P/S	0.80
P/B	1.56
P/C	12.51
P/FCF	17.39
EV/EBITDA	8.72
EV/Sales	1.14
Quick Ratio	1.54
Current Ratio	2.33
Debt/Eq	0.80
LT Debt/Eq	0.77
Option/Short	Yes / Yes

EPS (ttm)	5.31
EPS next Y	7.06
EPS next Q	1.96
EPS this Y	103.55%
EPS next Y	10.82%
EPS next 5Y	29.42%
EPS past 3/5Y	-57.90% -20.41%
Sales past 3/5Y	-4.36% 7.33%
EPS Y/Y TTM	1535.96%
Sales Y/Y TTM	15.23%
EPS Q/Q	111.57%
Sales Q/Q	22.93%
Earnings	Jun 25 BMO
EPS/Sales Surpr.	1.84% 3.40%

Insider Own	0.84%
Insider Trans	-1.57%
Inst Own	95.41%
Inst Trans	1.98%
ROA	7.09%
ROE	13.79%
ROIC	7.42%
Gross Margin	18.24%
Oper. Margin	9.08%
Profit Margin	6.72%
SMA20	-6.31%
SMA50	-10.04%
SMA200	-6.06%
Trades

Shs Outstand	110.70M
Shs Float	109.69M
Short Float	4.24%
Short Ratio	4.00
Short Interest	4.65M
52W High	84.87 -24.98%
52W Low	49.66 28.21%
Volatility	2.88% 3.63%
ATR (14)	2.44
RSI (14)	40.96
Beta	1.53
Rel Volume	0.00
Avg Volume	1.16M
Volume	0

Perf Week	1.55%
Perf Month	-13.46%
Perf Quarter	-3.22%
Perf Half Y	-9.83%
Perf YTD	-8.02%
Perf Year	22.18%
Perf 3Y	13.84%
Perf 5Y	107.19%
Perf 10Y	260.12%
Recom	1.79
Target Price	80.09
Prev Close	63.67
Price	63.67
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-26	Upgrade	BNP Paribas Exane	Neutral → Outperform	$75
Jun-04-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$77
May-22-26	Initiated	Barclays	Equal Weight	$75
May-14-26	Upgrade	UBS	Neutral → Buy	$89
Apr-01-26	Initiated	Goldman	Neutral	$74
Mar-25-26	Resumed	KeyBanc Capital Markets	Sector Weight
Dec-10-25	Upgrade	Jefferies	Hold → Buy	$78
Dec-05-25	Upgrade	JP Morgan	Neutral → Overweight	$78
Oct-24-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$68
Oct-22-25	Downgrade	Jefferies	Buy → Hold	$70
Oct-17-25	Upgrade	Citigroup	Neutral → Buy	$65
Aug-14-25	Initiated	Wells Fargo	Overweight	$61
May-30-25	Initiated	JP Morgan	Neutral	$52
May-27-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Jan-10-25	Upgrade	UBS	Sell → Neutral	$56 → $54
Jan-03-25	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-19-24	Resumed	Morgan Stanley	Equal-Weight	$65
Dec-12-24	Downgrade	UBS	Buy → Sell	$56
Dec-02-24	Initiated	Goldman	Buy	$75
Oct-09-24	Downgrade	Wolfe Research	Outperform → Peer Perform

Show Previous Ratings

Jun-25-26 07:00PM	Commercial Metals Co (CMC) Q3 2026 Earnings Call Highlights: Record Growth in Core EBITDA and ... (GuruFocus.com) -6.60%
06:53AM	Commercial Metals: Fiscal Q3 Earnings Snapshot (Associated Press)
06:45AM	CMC Reports Third Quarter of Fiscal 2026 Results (PR Newswire)
04:44AM	Earnings Calendar: McCormick results follow poor share price performance of late (MarketWatch)
Jun-24-26 08:34AM	CMC Announces Quarterly Dividend of $0.20 Per Share (PR Newswire)
09:58AM	Loading…
Jun-04-26 09:58AM	Broadcom downgraded, UnitedHealth upgraded: Wall Street's top analyst calls (The Fly)
May-27-26 06:45AM	CMC to Host 2026 Investor Day on August 5, 2026 (PR Newswire)
May-26-26 04:15PM	CMC Announces Third Quarter Fiscal 2026 Conference Call Webcast Details (PR Newswire)
May-14-26 10:24AM	Whats Next for Cleveland-Cliffs Stock? (Trefis)
Apr-14-26 06:25AM	JPMorgan tops earnings estimates on trading, investment banking strength (Proactive)
03:52AM	Nasdaq leads Wall Street higher as oil slides with Iran talks and earnings in focus (Proactive)
03:52AM	Nasdaq jumps, Dow heads higher with Iran talks and earnings in focus (Proactive)
03:52AM	Nasdaq jumps but Dow inches up with Iran talks and earnings in focus (Proactive)
03:52AM	Dow Jones set to open flat as Iran talks and bank earnings in focus (Proactive)
Apr-13-26 04:15PM	CMC Announces Appointment of Michael "Mike" Dumais to Board of Directors (PR Newswire)
10:15AM	Loading…
Apr-06-26 10:15AM	JPMorgan CEO Jamie Dimon warns of geopolitical, regulatory and AI risks in annual shareholder letter (Proactive)
10:15AM	JPMorgan CEO Dimon warns of geopolitical, regulatory and AI risks (Proactive)
Apr-01-26 07:18PM	US Set to Roll Out Tiered Tariffs on Steel, Aluminum Imports (Bloomberg)
Mar-26-26 04:43PM	Commercial Metals Company Q2 2026 Earnings Call Summary (Moby)
07:09AM	Commercial Metals Sees Further Growth In Second Half; Boosts Dividend 11% - Update (RTT News)
06:52AM	Commercial Metals: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	CMC Reports Second Quarter of Fiscal 2026 Results (PR Newswire)
05:31AM	Argan earnings on tap after shares surge 280% in just 12 months (MarketWatch)
04:18AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to retreat as oil rises on Day 26 of Iran conflict (MarketWatch)
Mar-25-26 08:49AM	CMC Announces an 11% Increase in Quarterly Dividend (PR Newswire)
Mar-19-26 03:52PM	JPMorgan analysts cut S&P 500 target, flagging market complacency despite oil shock (Proactive)
Mar-05-26 06:15PM	Methanex (MEOH) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-26-26 04:15PM	CMC Announces Second Quarter Fiscal 2026 Conference Call Webcast Details (PR Newswire)
Feb-25-26 11:11AM	Is CMC's North America Steel Group Segment Set for Long-Term Growth? (Zacks)
09:12AM	Do Options Traders Know Something About Commercial Metals Stock We Don't? (Zacks)
11:13AM	Loading…
Feb-24-26 11:13AM	CMC vs. CRS: Which Steel Stock Is the Better Buy Right Now? (Zacks)
Feb-23-26 11:23AM	Can CRS's Brownfield Expansion Project Fuel Long-Term Growth? (Zacks)
Feb-18-26 11:35AM	Can Commercial Metals' TAG Program Drive Margin Expansion? (Zacks)
Feb-13-26 10:02AM	Stocks Edge Lower as AI Fears Linger (Barchart)
Feb-11-26 10:59AM	CMC Jumps 69% in a Year: What's the Right Strategy for Investors Now? (Zacks)
Feb-02-26 01:14PM	Carpenter Technology Q2 Earnings Beat Estimates, Revenues Rise 8% Y/Y (Zacks)
Jan-29-26 03:00PM	4 GARP Stocks With Attractive PEG Ratios and Strong Growth Outlooks (Zacks)
12:20PM	Earnings Estimates Rising for Commercial Metals (CMC): Will It Gain? (Zacks)
Jan-28-26 12:22PM	CMC vs. NUE: Which US Steel Giant Is the Better Buy Right Now? (Zacks)
Jan-27-26 04:52PM	CMC Named to Corporate Knights' 2026 Global 100 Most Sustainable Corporations (PR Newswire)
12:31PM	Can Commercial Metals' Recent Acquisitions Fuel Long-Term Growth? (Zacks)
09:40AM	Should Value Investors Buy Commercial Metals (CMC) Stock? (Zacks)
Jan-23-26 12:00PM	Commercial Metals (CMC) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-20-26 03:00PM	Avoid Value Traps and Buy These 4 PEG-Based Stocks Now (Zacks)
Jan-19-26 07:41AM	POSCO Advances Automation With Yaskawa Industrial Robots Deal (Zacks)
06:16AM	Best Growth Stocks to Buy for January 19th (Zacks)
Jan-16-26 01:18PM	JP Morgan Predicts Mixed Q4 Steel Earnings Despite Steel Rally (Benzinga)
08:38AM	4 Women-Run Company Stocks Building Durable Growth Stories (Zacks)
Jan-15-26 01:14PM	Goldman Sachs Lifts Commercial Metals Company (CMC) Price Target Buoyed By Position in Steel Market (Insider Monkey)
Jan-12-26 12:59PM	Should Commercial Metals Be Part of Your Portfolio Post Q1 Results? (Zacks)
Jan-09-26 12:45PM	Looking for a Growth Stock? 3 Reasons Why Commercial Metals (CMC) is a Solid Choice (Zacks)
06:59AM	5E Advanced Materials Boric Acid Validated for LCD Glass Applications (Zacks)
06:04AM	Best Growth Stocks to Buy for January 9th (Zacks)
Jan-08-26 06:00PM	Commercial Metals Co (CMC) Q1 2026 Earnings Call Highlights: Record Earnings and Strategic ... (GuruFocus.com)
02:20PM	Commercial Metals Q1 Earnings Call Highlights (MarketBeat)
09:43AM	Commercial Metals Warns Of Near-Term Profit Hit From Acquisition Costs, Seasonal Steel Slump (Benzinga)
09:31AM	Zacks.com featured highlights include Animal Health, Commercial Metals, Fox and Adtalem Global Education (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Commercial Metals (CMC) Q1 Earnings (Zacks)
07:03AM	BASF Launches Key Steam Cracker at New Zhanjiang Verbund Site (Zacks)
06:56AM	Commercial Metals: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
06:51AM	Should You Buy, Sell or Hold CMC Stock Before Q1 Earnings Release? (Zacks)
06:45AM	CMC Reports First Quarter of Fiscal 2026 Results (PR Newswire)
05:45AM	Earnings to put Commercial Metals' recent share price surge to the test (MarketWatch)
05:12AM	Stock Market Today: Dow, S&P 500 and Nasdaq point to lower open; Nvidia in focus on China chip sales hope; precious metals retreat (MarketWatch)
Jan-07-26 03:00PM	4 PEG-Based GARP Picks for Navigating Early-2026 Market Uncertainty (Zacks)
04:42AM	Best Growth Stocks to Buy for January 7th (Zacks)
Jan-06-26 08:53AM	4 Steel Producer Stocks In Focus as Industry Gains on Price Recovery (Zacks)
04:10AM	Zacks.com featured highlights include Jabil, Ciena, Commercial Metals and Plains All American Pipeline (Zacks)
Jan-05-26 12:00PM	What Makes Commercial Metals (CMC) a Strong Momentum Stock: Buy Now? (Zacks)
09:30AM	Why Relative Price Strength Matters More Heading Into 2026 (Zacks)
06:45AM	CMC Announces Quarterly Dividend of $0.18 Per Share (PR Newswire)
Jan-04-26 07:45AM	December jobs numbers get data back on track during first full week of trading in 2026: What to watch (Yahoo Finance)
Jan-03-26 08:40AM	Stock Market Week Ahead: December Jobs, CES (Investor's Business Daily)
Jan-02-26 01:13PM	Acuity Stock, Fast-Growing Data Center Operator Headline 2026 Earnings Calendar (Investor's Business Daily)
Dec-29-25 12:20PM	Why Commercial Metals (CMC) Might be Well Poised for a Surge (Zacks)
09:20AM	Best Growth Stocks to Buy for December 29th (Zacks)
06:06AM	Zacks.com featured highlights include Ciena, EverQuote, PJT Partners and Commercial Metals (Zacks)
Dec-26-25 10:58AM	4 Top-Ranked Liquid Stocks to Enhance Portfolio Returns in 2026 (Zacks)
Dec-24-25 03:00PM	3 Attractive PEG-Driven Value Stocks to Pick for 2026 (Zacks)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Commercial Metals (CMC) (Zacks)
04:25AM	Best Growth Stocks to Buy for Dec. 24 (Zacks)
Dec-23-25 01:45PM	The Best Surging "Strong Buy" Stocks to Buy in 2026 (Zacks)
08:01AM	ICL Strengthens Food Ingredients Platform With Bartek Acquisition (Zacks)
Dec-19-25 12:11PM	Earnings Calendar Preview: Defense Stock AAR, Coatings Firm AZZ Lead January Profit Parade (Investor's Business Daily)
08:55AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Commercial Metals (CMC) (Zacks)
07:25AM	Steel Dynamics Projects Sequentially Lower Q4 Earnings on Seasonality (Zacks)
06:45AM	Commercial Metals Applauds Preliminary Ruling Against Algerian Rebar (PR Newswire)
Dec-18-25 04:15PM	CMC Publishes 2025 Sustainability Report (PR Newswire)
07:43AM	Nucor Expects Q4 Earnings to Dip on Seasonality, Stays Bullish on 2026 (Zacks)
Dec-17-25 04:15PM	Commercial Metals Announces Credit Facility Amendment (PR Newswire)
10:14AM	Can These 5 Relative Price Strength Stocks Lead in 2026? (Zacks)
09:40AM	Are Basic Materials Stocks Lagging Barrick Mining Corporation (B) This Year? (Zacks)
Dec-16-25 12:00PM	Commercial Metals (CMC) Is Up 5.53% in One Week: What You Should Know (Zacks)
07:04AM	5 High Earnings Yield Value Picks Ahead of Key Economic Reports (Zacks)
Dec-15-25 04:19PM	Commercial Metals Completes Acquisition of Foley Products Company (PR Newswire)
09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 08:30AM	4 Steel Stocks That Have Gained More Than 40% YTD Amid Price Recovery (Zacks)
07:23AM	Best Growth Stocks to Buy for December 11th (Zacks)
04:07AM	Zacks.com featured highlights include Centerra Gold, Commercial Metals, Vista Energy and Credicorp (Zacks)
Dec-10-25 03:00PM	4 PEG-Based GARP Picks Positioned to Offer Consistent Returns (Zacks) +5.12%

Commercial Metals Co. engages in the manufacture, recycling, and marketing of steel and metal products. It operates through the North America and Europe segments. The North America segment focuses on the network of recycling facilities, steel mills, and fabrication operations. The Europe segment includes a network of recycling facilities, an EAF mini mill, and fabrication operations located in Poland. The company was founded by Moses Feldman in 1915 and is headquartered in Irving, TX.

CEOMr. Peter R. Matt

Senior VP & CFOMr. Paul J. Lawrence CPA

Senior VPMs. Jody K. Absher J.D.

Senior VP & Chief Strategy OfficerMr. Kekin M. Ghelani

Senior Vice President of Operational & Commercial ExcellenceMr. Ty L. Garrison

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MATT PETER R	President and CEO	Jul 10 '26	Buy	61.30	8,230	504,499	181,522	Jul 13 11:49 AM
DURBIN JENNIFER J	Fmr. Chief HR & Comm. Officer	Feb 03 '26	Sale	79.97	25,050	2,003,248	52,880	Feb 04 02:39 PM
DURBIN JENNIFER J	Former Officer	Feb 03 '26	Proposed Sale	79.97	25,050	2,003,248		Feb 03 10:37 AM
ARRIOLA DENNIS V	Director	Jan 20 '26	Buy	74.69	2,000	149,380	9,238	Jan 22 10:15 AM
Halloran Brian N.	SVP, N. America Steel Group	Oct 31 '25	Sale	59.87	6,232	373,110	58,055	Nov 04 08:41 AM
Halloran Brian N.	Officer	Oct 31 '25	Proposed Sale	59.87	6,232	373,120		Oct 31 12:52 PM
McPherson John R	Director	Oct 20 '25	Buy	58.09	1,722	100,037	6,722	Oct 21 01:15 PM

PRQR ProQR Therapeutics N.V daily Stock Chart

Peers: KPTI ADAG CAMP CNTN CNTX IFRX PLYX RNA TENX TLSA

Index	-
Market Cap	234.75M
Enterprise Value	157.09M
Income	-52.71M
Sales	15.53M
Book/sh	0.41
Cash/sh	0.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 18, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	15.12
P/B	4.13
P/C	2.51
P/FCF	-
EV/EBITDA	-
EV/Sales	10.12
Quick Ratio	2.48
Current Ratio	2.48
Debt/Eq	0.36
LT Debt/Eq	0.24
Option/Short	Yes / Yes

EPS (ttm)	-0.50
EPS next Y	-0.57
EPS next Q	-0.13
EPS this Y	-14.96%
EPS next Y	-9.31%
EPS next 5Y	4.66%
EPS past 3/5Y	21.80% 15.68%
Sales past 3/5Y	68.13% -
EPS Y/Y TTM	-44.36%
Sales Y/Y TTM	-23.73%
EPS Q/Q	-47.57%
Sales Q/Q	-49.99%
Earnings	May 12 BMO
EPS/Sales Surpr.	-9.12% -54.37%

Insider Own	32.49%
Insider Trans	1.05%
Inst Own	26.99%
Inst Trans	-1.64%
ROA	-37.92%
ROE	-81.98%
ROIC	-98.02%
Gross Margin	79.71%
Oper. Margin	-346.94%
Profit Margin	-339.39%
SMA20	-0.74%
SMA50	5.50%
SMA200	-9.59%
Trades

Shs Outstand	105.36M
Shs Float	89.78M
Short Float	1.34%
Short Ratio	1.23
Short Interest	1.20M
52W High	3.10 -45.16%
52W Low	1.33 27.82%
Volatility	9.71% 11.07%
ATR (14)	0.16
RSI (14)	51.10
Beta	0.07
Rel Volume	0.00
Avg Volume	973.76K
Volume	0

Perf Week	-1.16%
Perf Month	20.57%
Perf Quarter	-8.11%
Perf Half Y	-19.05%
Perf YTD	-15.84%
Perf Year	-26.72%
Perf 3Y	1.19%
Perf 5Y	-72.27%
Perf 10Y	-64.73%
Recom	1.00
Target Price	8.99
Prev Close	1.70
Price	1.70
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	Oppenheimer	Outperform	$9
Apr-29-25	Resumed	Cantor Fitzgerald	Overweight	$8
Apr-29-25	Initiated	Evercore ISI	Outperform	$5
Mar-10-25	Upgrade	Citigroup	Neutral → Buy	$4
Jan-10-25	Initiated	Oppenheimer	Outperform	$15
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy	$6 → $14
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$2
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$1.50 → $5
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$0.80 → $5
Feb-14-22	Downgrade	Citigroup	Buy → Neutral	$37 → $1.70
Feb-11-22	Downgrade	Stifel	Buy → Hold	$20 → $3
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-01-22	Initiated	Raymond James	Strong Buy	$19
May-03-21	Initiated	Stifel	Buy	$20
Mar-25-21	Reiterated	Citigroup	Buy	$33 → $44
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight	$22
Mar-12-19	Reiterated	Chardan Capital Markets	Buy	$21 → $25
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy	$32
Sep-19-18	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Jun-25-26 06:35AM	ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -13.54%
06:25AM	ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform (GlobeNewswire)
May-12-26 07:00AM	ProQR Announces First Quarter 2026 Operating and Financial Results (GlobeNewswire)
May-11-26 08:00AM	ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer RNA Editing Platform (GlobeNewswire)
May-04-26 08:00AM	ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 (GlobeNewswire) +5.81%
08:00AM	Loading…
Apr-30-26 08:00AM	ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors (GlobeNewswire)
Apr-08-26 04:00PM	ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event (GlobeNewswire) +7.65% +8.20%
08:00AM	ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board (GlobeNewswire)
Mar-25-26 08:00AM	ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 (GlobeNewswire) +6.04%
Mar-12-26 09:18AM	ProQR: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	ProQR Announces Year End 2025 Operating and Financial Results (GlobeNewswire)
Mar-10-26 08:30AM	Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-03-26 04:30PM	ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference (GlobeNewswire) -5.06% +13.33%
Feb-26-26 06:45PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-09-26 08:00AM	ProQR Announces Planned Changes to Board Composition (GlobeNewswire)
08:00AM	Loading…
Jan-08-26 08:00AM	ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook (GlobeNewswire)
Dec-01-25 08:00AM	ProQR to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) -9.40%
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.14%
07:08AM	ProQR: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ProQR Announces Third Quarter 2025 Operating and Financial Results (GlobeNewswire)
Oct-28-25 08:20AM	Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-20-25 08:00AM	ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 (GlobeNewswire) +9.71%
Oct-13-25 08:30AM	ProQR to Participate in Upcoming Investor Conferences in October 2025 (GlobeNewswire)
Aug-08-25 02:02PM	ProQR: Q2 Earnings Snapshot (Associated Press Finance) +5.85%
Aug-07-25 08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	ProQR Announces Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	ProQR Announces Upcoming Presentation at RNA Editing Summit (GlobeNewswire)
Jun-26-25 04:30PM	ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP (GlobeNewswire) -5.56%
May-12-25 08:00AM	ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences (GlobeNewswire)
May-08-25 07:00AM	ProQR Announces First Quarter 2025 Operating and Financial Results (GlobeNewswire)
07:40AM	Loading…
May-07-25 07:40AM	Techne (TECH) Q3 Earnings and Revenues Beat Estimates (Zacks)
May-02-25 08:00AM	ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference (GlobeNewswire) +15.70%
May-01-25 08:00AM	ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 (GlobeNewswire)
Apr-29-25 04:31PM	ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald (TipRanks) +5.84%
04:05PM	ProQR Therapeutics initiated with an Outperform at Evercore ISI (TipRanks)
Apr-15-25 09:01AM	Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Apr-14-25 07:00AM	ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth (GlobeNewswire) +5.36%
Mar-13-25 07:00AM	ProQR Announces Year End 2024 Operating and Financial Results (GlobeNewswire) -5.95%
Dec-12-24 07:16AM	ProQR Therapeutics announces $8.1M in new funding from RSRT (TipRanks)
Dec-11-24 07:00AM	ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration (GlobeNewswire)
Dec-10-24 08:00AM	ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist (GlobeNewswire)
Dec-06-24 06:47AM	ProQR Therapeutics price target raised to $8 from $5 at JMP Securities (TipRanks)
Dec-05-24 08:00AM	ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 (GlobeNewswire)
Nov-08-24 07:26AM	ProQR Therapeutics sees cash runway into mid-2027 (TipRanks) +5.60%
Nov-07-24 07:00AM	ProQR Announces Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-25-24 04:45PM	ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire)
Oct-22-24 10:15PM	ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire) -6.67% -7.67%
04:01PM	ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire)
Oct-07-24 08:00AM	ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-10-24 04:30PM	ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-08-24 07:00AM	ProQR Announces Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +12.30%
Jun-18-24 08:00AM	ProQR Announces Presentation on its Axiomer RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
May-09-24 07:00AM	ProQR Announces First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-08-24 08:00AM	ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases (GlobeNewswire)
Apr-23-24 07:00AM	ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 (GlobeNewswire)
Apr-22-24 04:31PM	ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-19-24 07:00AM	ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio (GlobeNewswire) +6.99%
Mar-13-24 07:00AM	ProQR Announces Year End 2023 Operating and Financial Results (GlobeNewswire) +13.66%
Feb-15-24 07:00AM	ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing (GlobeNewswire)
Jan-19-24 07:00AM	ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024 (GlobeNewswire)
Jan-05-24 07:00AM	ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration (GlobeNewswire)
Dec-28-23 08:44AM	Is ProQR (PRQR) Stock a Solid Choice Right Now? (Zacks)
Dec-08-23 07:30AM	ProQR Therapeutics Announces Transaction Completed for Th a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire)
Nov-07-23 07:00AM	ProQR Announces Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +10.66%
Nov-06-23 07:00AM	ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing (GlobeNewswire)
Sep-28-23 08:00AM	ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-27-23 07:00AM	ProQR Therapeutics Provides Update on Ophthalmic Assets (GlobeNewswire)
Sep-07-23 08:00AM	ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 06:37AM	ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions (Simply Wall St.)
Aug-03-23 07:00AM	ProQR Announces Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-01-23 07:00AM	ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQRs Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire) +7.33%
Jul-06-23 07:00AM	ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
Jun-28-23 06:02AM	ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year (Simply Wall St.)
May-18-23 07:02AM	ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability (Simply Wall St.)
May-16-23 07:00AM	ProQR Announces First Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.29%
May-09-23 08:00AM	ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 (GlobeNewswire)
Apr-20-23 08:00AM	ProQR Announces Upcoming Investor Conferences in April and May (GlobeNewswire)
Apr-18-23 08:00AM	ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 (GlobeNewswire) -6.47%
Mar-29-23 12:30PM	Why Shares of ProQR Therapeutics Dropped on Wednesday (Motley Fool) -29.61%
08:00AM	ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event (GlobeNewswire)
Mar-14-23 08:00AM	ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing (GlobeNewswire) +7.85%
Mar-07-23 08:00AM	ProQR to Present at Upcoming Scientific and Industry Conferences (GlobeNewswire)
Feb-28-23 08:00AM	ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 (GlobeNewswire)
Feb-01-23 05:11AM	Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions account for 35% (Simply Wall St.)
Dec-29-22 11:36AM	Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More (Zacks) +10.13%
Dec-23-22 12:14PM	ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly (Zacks)
Dec-22-22 09:12AM	ProQR's stock jumps on expanded RNA deal with Lilly (MarketWatch) +63.64%
08:53AM	ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration (Benzinga)
06:15AM	ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform (GlobeNewswire)
06:00AM	Lilly and ProQR to Expand RNA Editing Collaboration (PR Newswire)
05:28AM	ProQR Therapeutics (NASDAQ:PRQR) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Nov-14-22 04:30PM	ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 (GlobeNewswire) +5.18%
Nov-11-22 05:54AM	ProQR Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 08:25AM	ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ProQR Announces Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-03-22 07:00AM	ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference (GlobeNewswire)
Aug-12-22 02:05PM	Raymond James Bullish On This Penny Stock's Reprioritized Pipeline (Benzinga) +5.51%
Aug-11-22 02:48PM	This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing (Benzinga)
07:00AM	ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs (GlobeNewswire)
Aug-04-22 10:25AM	ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

FounderMr. Daniel Anton de Boer

Co-FounderDr. Gerard Platenburg Ph.D.

Chief Financial OfficerMr. Dennis Hom

Chief People & Operations OfficerMs. Sheila Sponselee

Vice President of Investor Relations & Corporate CommunicationsMs. Sarah Cue Kiely

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
de Boer Daniel Anton	Chief Executive Officer	Jul 09 '26	Buy	1.74	150,000	261,000	300,000	Jul 13 08:00 AM
de Boer Daniel Anton	Chief Executive Officer	Jul 07 '26	Buy	1.59	150,000	238,500	150,000	Jul 08 02:55 PM
Filius Bart	Director	Jun 26 '26	Buy	1.54	150,000	231,000	150,000	Jun 30 04:01 PM

ANIX Anixa Biosciences Inc daily Stock Chart

Peers: ATYR COYA CYPH INO LONA NRXS CGTX KLRS NRXP KALA

| Held by: VTI VXF IWC

Index	-
Market Cap	104.11M
Enterprise Value	89.35M
Income	-10.03M
Sales	0.00M
Book/sh	0.43
Cash/sh	0.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Oct 07, 1983

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.17
P/C	7.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.79
Current Ratio	9.79
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.30
EPS next Y	-0.33
EPS next Q	-0.08
EPS this Y	6.35%
EPS next Y	-3.17%
EPS next 5Y	-1.16%
EPS past 3/5Y	9.05% 5.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	19.64%
Sales Y/Y TTM	-
EPS Q/Q	13.51%
Sales Q/Q	-
Earnings	Jun 05
EPS/Sales Surpr.	14.71% -

Insider Own	5.45%
Insider Trans	2.14%
Inst Own	14.97%
Inst Trans	-2.98%
ROA	-63.02%
ROE	-65.70%
ROIC	-68.66%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.69%
SMA50	9.12%
SMA200	-6.84%
Trades

Shs Outstand	33.92M
Shs Float	32.17M
Short Float	2.75%
Short Ratio	5.01
Short Interest	0.89M
52W High	5.46 -43.92%
52W Low	2.32 31.90%
Volatility	7.13% 8.98%
ATR (14)	0.22
RSI (14)	56.48
Beta	0.58
Rel Volume	0.00
Avg Volume	176.83K
Volume	0

Perf Week	0.33%
Perf Month	30.21%
Perf Quarter	13.75%
Perf Half Y	-10.53%
Perf YTD	-1.92%
Perf Year	-2.55%
Perf 3Y	-3.77%
Perf 5Y	-17.07%
Perf 10Y	-11.84%
Recom	1.00
Target Price	10.00
Prev Close	3.06
Price	3.06
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Initiated	Maxim Group	Buy	$10
Dec-23-22	Initiated	Chardan Capital Markets	Buy	$8
Apr-12-21	Initiated	H.C. Wainwright	Buy	$11

Jul-06-26 08:30AM	Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date (PR Newswire) -6.73%
Jun-30-26 06:35AM	Anixa Biosciences secures Korean patent for breast cancer vaccine (Pharmaceutical Business Review)
Jun-29-26 08:45AM	Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 (PR Newswire)
Jun-26-26 09:10AM	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +6.49%
Jun-11-26 09:05AM	Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium (PR Newswire) +5.53%
09:00AM	Loading…
Jun-01-26 09:00AM	Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance (PR Newswire)
May-11-26 08:55AM	Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy (PR Newswire)
May-01-26 09:15AM	Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
Apr-29-26 09:10AM	Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Apr-22-26 08:45AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting (PR Newswire) +9.03%
Apr-09-26 09:05AM	Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 (PR Newswire)
Apr-07-26 08:55AM	Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 (PR Newswire)
Apr-06-26 09:10AM	Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs (PR Newswire)
Apr-01-26 08:50AM	Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing (PR Newswire) +5.43%
Mar-30-26 09:05AM	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (PR Newswire)
10:38AM	Loading…
Mar-12-26 10:38AM	Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast (PR Newswire)
Mar-09-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Mar-02-26 09:10AM	Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress (PR Newswire)
Feb-23-26 08:55AM	Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat (PR Newswire)
Feb-10-26 03:50PM	Anixa Biosciences CEO Calls 2026 Pivotal as Breast Cancer Vaccine, Ovarian CAR-T Advance (MarketBeat)
Feb-09-26 08:00AM	Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation (PR Newswire)
07:31AM	EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues (Benzinga)
Feb-02-26 09:00AM	Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization (PR Newswire)
Jan-27-26 08:30AM	Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Dec-15-25 08:45AM	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic (PR Newswire) -8.94%
Dec-10-25 09:00AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 (PR Newswire)
Nov-17-25 08:15AM	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization (PR Newswire)
Nov-12-25 09:00AM	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Nov-10-25 10:30AM	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 (PR Newswire)
Nov-05-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:55AM	Loading…
08:55AM	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic (PR Newswire)
Oct-23-25 08:45AM	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference (PR Newswire)
Oct-20-25 08:25AM	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Oct-17-25 12:00PM	Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice (Zacks) -6.82%
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +8.03%
Oct-07-25 08:30AM	Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial (PR Newswire) +26.46%
Oct-02-25 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks)
Sep-22-25 08:05AM	Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium (PR Newswire) +5.76%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
09:40AM	Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-09-25 06:45PM	3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (MarketBeat)
Sep-08-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival (PR Newswire)
Sep-02-25 08:54AM	Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 09:13AM	Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-20-25 08:37AM	Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Aug-18-25 09:00AM	Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Aug-12-25 08:05AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology (PR Newswire)
Aug-08-25 09:15AM	Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference (PR Newswire)
Aug-04-25 08:45AM	Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial (PR Newswire) +8.31%
Jul-30-25 08:15AM	Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire)
Jul-25-25 09:40AM	Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-24-25 08:00AM	Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s (PR Newswire)
Jul-09-25 09:40AM	Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
Jun-26-25 12:00PM	ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? (Zacks)
Jun-23-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
08:00AM	Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Jun-20-25 07:30AM	Anixa Biosciences to Host an Investor Webcast on June 26, 2025 (PR Newswire)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire) +5.42%
Jun-10-25 12:00PM	What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? (Zacks)
07:00AM	Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage (PR Newswire)
Jun-09-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 (PR Newswire) +23.19%
Jun-05-25 12:00PM	All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy (Zacks)
09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
Jun-03-25 07:25AM	Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview (PR Newswire)
Jun-02-25 07:00AM	Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine (PR Newswire) +12.45%
May-19-25 08:00AM	Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones (PR Newswire)
May-12-25 08:00AM	Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-30-25 08:00AM	Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th (PR Newswire)
Apr-14-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio (PR Newswire)
Apr-11-25 09:40AM	Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-10-25 09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology (PR Newswire) +13.03%
07:45AM	EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent (Benzinga)
Apr-01-25 08:00AM	Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th (PR Newswire)
Mar-25-25 08:00AM	Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines (PR Newswire)
07:51AM	EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines (Benzinga)
Mar-24-25 08:00AM	Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine (PR Newswire)
07:46AM	EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine (Benzinga)
Mar-17-25 08:00AM	Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th (PR Newswire)
Mar-10-25 08:30AM	Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties (PR Newswire) -7.39%
Mar-03-25 08:00AM	Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th (PR Newswire) -9.84%
Feb-26-25 08:00AM	Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-25-25 07:30AM	Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' 'America Reports' (PR Newswire)
Feb-24-25 08:00AM	Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer (PR Newswire) -6.49%
Feb-18-25 08:00AM	Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Feb-14-25 07:00AM	Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview (PR Newswire)
Feb-11-25 08:30AM	Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum (PR Newswire)
Feb-04-25 08:30AM	Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention (PR Newswire) +6.07%
Jan-21-25 08:30AM	Anixa Biosciences CEO Provides Letter to Shareholders (PR Newswire) +16.60%
Dec-06-24 08:30AM	iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 (ACCESS Newswire)
Dec-04-24 08:30AM	Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 (PR Newswire)
Nov-22-24 08:15AM	Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset (PR Newswire)
Nov-18-24 08:20AM	Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Nov-08-24 01:17PM	Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Nov-06-24 08:30AM	Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Oct-31-24 08:15AM	Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 (PR Newswire)
Oct-28-24 08:30AM	Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +22.15%
Oct-16-24 05:42AM	Anixa Biosciences administers second CAR-T dose in ovarian cancer trial (Clinical Trials Arena)
Oct-15-24 09:00AM	Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

CEODr. Amit Kumar Ph.D.

MBAMr. Michael J. Catelani CPA

Chief Development Officer & Chair Breast Cancer Clinical Advisory BoardDr. Pamela D. Garzone Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KUMAR AMIT	Chief Executive Officer	Jul 10 '26	Buy	3.04	5,000	15,200	635,812	Jul 13 08:59 AM
Titterton Lewis H jr	Director	Jun 16 '26	Buy	2.64	2,836	7,487	972,170	Jun 17 11:21 AM
KUMAR AMIT	Chief Executive Officer	Jun 12 '26	Buy	2.50	21,000	52,500	630,812	Jun 16 09:00 AM
Baskies Arnold M	Director	Jan 28 '26	Buy	3.04	10,000	30,400	135,000	Jan 29 08:58 AM
Titterton Lewis H jr	Director	Dec 15 '25	Option Exercise	2.92	16,000	46,720	969,334	Dec 16 08:56 AM
KUMAR AMIT	Chief Executive Officer	Oct 30 '25	Option Exercise	2.92	200,000	584,000	779,925	Oct 31 09:13 AM
Titterton Lewis H jr	Director	Jul 31 '25	Buy	3.08	10,000	30,800	953,334	Aug 04 09:00 AM
KUMAR AMIT	Chief Executive Officer	Jul 30 '25	Buy	3.16	5,000	15,800	579,925	Jul 31 09:00 AM
Baskies Arnold M	Director	Jul 18 '25	Buy	3.39	5,000	16,950	125,000	Jul 21 08:30 AM

TDIC

Dreamland Ltd

IPX

IperionX Ltd ADR

CMC

Commercial Metals Co

PRQR

ProQR Therapeutics N.V

ANIX

Anixa Biosciences Inc

Upgrade your Finviz experience